Sign up now with your company or organization email and enjoy a
1-week free trial!
Contract Details
| Title |
Brineura 150 Mg Solution For Infusion () Slovakia |
|||
|---|---|---|---|---|
You can sign up and unlock it for freeAccess to Public and Private Sector Business Opportunities for 200+ Countries |
||||
| Country | ||||
| Language | English | |||
| Organization | ||||
| Published Date | 29.08.2024 | |||
| Awarded Date | 06.05.2019 | |||
| Overview | Contract Award's Details : Brineura 150 Mg Solution For Infusion () Detská Fakultná Nemocnica S Poliklinikou Banská Bystrica 37957937 Námestie L.Svobodu 4 Banská Bystrica 974 09 Slovakia Contact Person: Ing. Gabriela Gondová Tel: +421 484726500 E-Mail: Obstaravanie@Dfnbb.Sk Fax: +421 48472 Brineura 150 Mg Solution For Infusion () Contract award notice: Brineura 150 mg solution for infusion () brineura 150 mg solution for infusion (sukl 4681c) contains the active substance cerliponase alfa, Which belongs to a group of medicines known as enzyme replacement therapy. Brineura (cerliponase alfa) is the first approved treatment for any form of batten~s disease and is indicated to slow disease progression in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (cln2), Also known as tripeptidyl deficiency peptidase 1 (tpp1). Cln2 is an extremely rare and rapidly developing brain disorder that affects approximately 20 children born in the united states per year, Less than 1 disease per million americans. Brineura is the first enzyme replacement therapy that is administered directly to the brain fluid that treats the underlying cause of cln2 by helping to replace the missing tpp1 enzyme in affected children. It is used to treat patients with neuronal ceroid lipofuscinosis type 2 (cln2), Also known as tripeptidyl peptidase 1 (tpp1) deficiency. Cln2 disease is a rare genetic disorder that affects children. People with cln2 have little or no enzyme called tpp1, Which causes the accumulation of substances called lysosomal storage substances. In people with cln2, These substances accumulate in some parts of the body, Especially in the brain. This drug replaces the missing enzyme called tppa, Thereby minimizing the accumulation of lysosomal storage substances. This medicine works by slowing the progress of the disease. The recommended dose is 300 mg of cerliponase alfa given once every 2 weeks by intracerebroventricular infusion, Which means that it is administered to the cerebrospinal fluid by infusion through a surgically implanted reservoir and catheter. Date of contract award: : 04/24/2019 v.2.2) information about offers bids received: 1 number of tenders received: 1 health Slovakia Contract value : 570,932.00 SKK Contractors : TRANSMEDIC SLOVAKIA, SRO See in details 07/05/2019 07/08/2019 13234103 07/05/2019 Detská Fakultná Nemocnica S Poliklinikou Banská Bystrica 37957937 Námestie L.Svobodu 4 Banská Bystrica 974 09 Slovakia Contact Person: Ing. Gabriela Gondová Tel: +421 484726500 E-Mail: Obstaravanie@Dfnbb.Sk Fax: +421 48472 Address : Slovakia Slovakia Contract Awards Slovakia 210698-2019 See in details 07/08/2019 570,932.00 SKK | |||
| NAICS |
-
|
|||
| CPVS | ||||
| UNSPSC | ||||
| Regions | ||||
| Sectors |
Healthcare and Medicine
Automobiles and Auto Parts
Non-Renewable Energy
Supply
Solar Photovoltaic PV Energy
Roads and Highways-Bridge
Law and Legal
Printing and Publishing
Cement and Asbestos Products
Railways-Rail-Railroad
Defence and Security
Electricity
Construction
Energy-Power and Electrical
Computer Hardwares and Consumables
Steel
Construction Materials
Marine
|
|||
| Contractor | ||||
| Contract Value |
570,932.00 SKK
|
URL | ||
| Share | ||||
Slovakia
| Title |
|---|
Brineura 150 Mg Solution For Infusion () Slovakia |
| Country |
| Language |
| English |
| Organization |
| Published Date |
| 29.08.2024 |
| Awarded Date |
| 06.05.2019 |
| Overview |
| Contract Award's Details : Brineura 150 Mg Solution For Infusion () Detská Fakultná Nemocnica S Poliklinikou Banská Bystrica 37957937 Námestie L.Svobodu 4 Banská Bystrica 974 09 Slovakia Contact Person: Ing. Gabriela Gondová Tel: +421 484726500 E-Mail: Obstaravanie@Dfnbb.Sk Fax: +421 48472 Brineura 150 Mg Solution For Infusion () Contract award notice: Brineura 150 mg solution for infusion () brineura 150 mg solution for infusion (sukl 4681c) contains the active substance cerliponase alfa, Which belongs to a group of medicines known as enzyme replacement therapy. Brineura (cerliponase alfa) is the first approved treatment for any form of batten~s disease and is indicated to slow disease progression in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (cln2), Also known as tripeptidyl deficiency peptidase 1 (tpp1). Cln2 is an extremely rare and rapidly developing brain disorder that affects approximately 20 children born in the united states per year, Less than 1 disease per million americans. Brineura is the first enzyme replacement therapy that is administered directly to the brain fluid that treats the underlying cause of cln2 by helping to replace the missing tpp1 enzyme in affected children. It is used to treat patients with neuronal ceroid lipofuscinosis type 2 (cln2), Also known as tripeptidyl peptidase 1 (tpp1) deficiency. Cln2 disease is a rare genetic disorder that affects children. People with cln2 have little or no enzyme called tpp1, Which causes the accumulation of substances called lysosomal storage substances. In people with cln2, These substances accumulate in some parts of the body, Especially in the brain. This drug replaces the missing enzyme called tppa, Thereby minimizing the accumulation of lysosomal storage substances. This medicine works by slowing the progress of the disease. The recommended dose is 300 mg of cerliponase alfa given once every 2 weeks by intracerebroventricular infusion, Which means that it is administered to the cerebrospinal fluid by infusion through a surgically implanted reservoir and catheter. Date of contract award: : 04/24/2019 v.2.2) information about offers bids received: 1 number of tenders received: 1 health Slovakia Contract value : 570,932.00 SKK Contractors : TRANSMEDIC SLOVAKIA, SRO See in details 07/05/2019 07/08/2019 13234103 07/05/2019 Detská Fakultná Nemocnica S Poliklinikou Banská Bystrica 37957937 Námestie L.Svobodu 4 Banská Bystrica 974 09 Slovakia Contact Person: Ing. Gabriela Gondová Tel: +421 484726500 E-Mail: Obstaravanie@Dfnbb.Sk Fax: +421 48472 Address : Slovakia Slovakia Contract Awards Slovakia 210698-2019 See in details 07/08/2019 570,932.00 SKK |
| NAICS |
| - |
| CPVS |
| Tanks, reservoirs, containers and pressure vessels Reservoirs Forms Enzymes Catheters |
| UNSPSC |
| Reservoirs Awards Storage General goods storage Drug cases Catheter room Infusions |
| Regions |
| Eastern Europe Europe |
| Sectors |
| Healthcare and Medicine Automobiles and Auto Parts Non-Renewable Energy Supply Solar Photovoltaic PV Energy Roads and Highways-Bridge Law and Legal Printing and Publishing Cement and Asbestos Products Railways-Rail-Railroad Defence and Security Electricity Construction Energy-Power and Electrical Computer Hardwares and Consumables Steel Construction Materials Marine |
| Contractor |
| Contract Value |
|
570,932.00 SKK
|
| URL |
|
|
| Share |
To be notified
when a tender matching your filter is
published
To Follow
Tenders
Add New Tender Alert
To Follow
Contracts
Add New Contract Alert
To Follow
Fairs
Add New Fair Alert
Similar Contracts